Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

(2021) Juan Du et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

(2021) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

(2021) Darrell White et al.   JOURNAL OF CLINICAL ONCOLOGY

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

(2020) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)

(2020) Jin Liu et al.   LEUKEMIA

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016

(2019) Jiangmei Liu et al.   Journal of Hematology & Oncology

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

(2018) Christian Argueta et al.   Oncotarget

Global Burden of Multiple Myeloma

(2018) Andrew J. Cowan et al.   JAMA Oncology

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

(2014) C. Blimark et al.   HAEMATOLOGICA

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients

(2010) M. K. Kim et al.   ANNALS OF ONCOLOGY

A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients

(2010) Yoshinori Shimamoto et al.   EUROPEAN JOURNAL OF HAEMATOLOGY